Key facts
- This page summarizes Perry C. Siatis's Form 4 filing for AbbVie Inc. (ABBV).
- 7 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 27 Feb 2026, 17:00.
Perry C. Siatis - 25 Feb 2026 Form 4 Insider Report for AbbVie Inc. (ABBV)
- Reporting relationship
- EVP, GC AND SECRETARY
- Issuer ticker
- ABBV
- Reported as of
- 25 Feb 2026
- Net transaction value
- -$5,147,630
- SEC form
- 4
- Accepted by SEC
- 27 Feb 2026, 17:00:05 UTC
- Prior SEC filing
- 20 Feb 2026
- Next SEC filing
- 03 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ T.O. Odutayo, Attorney-in-Fact for Perry C. Siatis
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Perry C. Siatis filed Form 4 for AbbVie Inc. (ABBV) on 27 Feb 2026.
Change
- Previous filing in this sequence was filed on 20 Feb 2026.
- Current net transaction value: -$5,147,630.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001951400
Primary reporting owner
Siatis Perry C
- Relationship
- EVP, GC AND SECRETARY
- Address
- 1 N. WAUKEGAN ROAD, NORTH CHICAGO
- Signature
- /s/ T.O. Odutayo, Attorney-in-Fact for Perry C. Siatis
- Signature date
- 27 Feb 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ABBV
transaction
Common Stock, $0.01 par value
Options Exercise
- Transaction value
- $1,094,321
- Shares
- +7,314
- Change %
- +19%
- Price
- $149.62
- Shares after
- 45,451
- Date
- 25 Feb 2026
- Ownership
- Direct
ABBV
transaction
Common Stock, $0.01 par value
Options Exercise
- Transaction value
- $1,362,802
- Shares
- +7,775
- Change %
- +17%
- Price
- $175.28
- Shares after
- 53,226
- Date
- 25 Feb 2026
- Ownership
- Direct
ABBV
transaction
Common Stock, $0.01 par value
Options Exercise
- Transaction value
- $1,406,335
- Shares
- +7,292
- Change %
- +14%
- Price
- $192.86
- Shares after
- 60,518
- Date
- 25 Feb 2026
- Ownership
- Direct
ABBV
transaction
Common Stock, $0.01 par value
Sale
- Transaction value
- $5,147,630
- Shares
- -22,381
- Change %
- -37%
- Price
- $230.00
- Shares after
- 38,137
- Date
- 25 Feb 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ABBV
transaction
Derivative
Option (Right to buy)
Options Exercise
- Transaction value
- $1,094,321
- Shares
- -7,314
- Change %
- -100%
- Price
- $149.62
- Shares after
- 0
- Date
- 25 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,314
- Exercise price
- $149.62
- Footnotes
- F1
ABBV
transaction
Derivative
Option (Right to buy)
Options Exercise
- Transaction value
- $1,362,802
- Shares
- -7,775
- Change %
- -50%
- Price
- $175.28
- Shares after
- 7,774
- Date
- 25 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,775
- Exercise price
- $175.28
- Footnotes
- F2
ABBV
transaction
Derivative
Option (Right to buy)
Options Exercise
- Transaction value
- $1,406,335
- Shares
- -7,292
- Change %
- -33%
- Price
- $192.86
- Shares after
- 14,583
- Date
- 25 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,292
- Exercise price
- $192.86
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 3 footnotes
Footnote F1
Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 7,315 on February 16, 2024, 7,315 on February 16, 2025, and 7,314 on February 16, 2026.
Footnote F2
Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 7,775 on February 15, 2025 and 7,775 on February 15, 2026, and becomes exercisable as to 7,774 shares on February 15, 2027.
Footnote F3
Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 7,292 shares on February 13, 2026 and becomes exercisable in annual increments of 7,292 on February 13, 2027, and 7,291 on February 13, 2028.